bio2018-mybio-sessionicon-companypres

Sterotherapeutics LLC Company Presentation

2:15 PM–2:30 PM Jun 3, 2019 (US - Eastern)

Theater 1

Description

SteroTherapeutics (Philadelphia, PA) is Philadelphia based biopharmaceutical company pursuing treatments for Cushing’s syndrome and non-alcoholic steatohepatitis (NASH). Company's lead candidate is a novel anti-glucocorticoid and G6PD inhibitor that has been studied in >100 patients.
SteroTherapeutics received orphan designation for ST-002 for the treatment of hyperglycemia, Non-Alcoholic Fatty Disease (NAFLD) and NASH in Cushing’s syndrome patients. ST-001 is in development for Non-alcoholic steatohepatitis (NASH) which has been predicted as the next major health epidemic.

Session ID: 562048

Tags